NASDAQ:TBPH Theravance Biopharma Q1 2026 Earnings Report $16.81 -0.12 (-0.71%) Closing price 04:00 PM EasternExtended Trading$16.88 +0.07 (+0.44%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Theravance Biopharma EPS ResultsActual EPS-$0.10Consensus EPS $0.03Beat/MissMissed by -$0.13One Year Ago EPSN/ATheravance Biopharma Revenue ResultsActual Revenue$17.70 millionExpected Revenue$17.78 millionBeat/MissMissed by -$84.00 thousandYoY Revenue GrowthN/ATheravance Biopharma Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateThursday, May 7, 2026Conference Call Time9:00AM ETUpcoming EarningsTheravance Biopharma's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Theravance Biopharma Earnings HeadlinesTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $19.40 Average PT from AnalystsJuly 16, 2026 | americanbankingnews.comTheravance Biopharma Stock Dividends | NASDAQ:TBPH | BenzingaJuly 13, 2026 | benzinga.comBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.July 20 at 1:00 AM | Awesomely (Ad)$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)June 29, 2026 | prnewswire.comTBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its ShareholdersJune 29, 2026 | businesswire.comShareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public ShareholdersJune 29, 2026 | prnewswire.comSee More Theravance Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email. Email Address About Theravance BiopharmaTheravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S. Food and Drug Administration for the maintenance treatment of chronic obstructive pulmonary disease (COPD). In addition to its marketed respiratory franchise, Theravance Biopharma maintains a diversified pipeline with clinical-stage programs in immunology and rare disease. Its immunology efforts include a gut-selective pan-JAK inhibitor being evaluated for inflammatory bowel diseases, while its rare disease portfolio features a norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. The company leverages internal research capabilities alongside collaborations and partnerships to advance its small-molecule candidates through clinical and regulatory milestones. Founded in 1998 as part of a respiratory research group of GlaxoSmithKline and later spun out as an independent entity in 2014, Theravance Biopharma is headquartered in South San Francisco, California. It operates research facilities in the Bay Area and maintains corporate offices in Dublin, Ireland, supporting its global clinical programs. The company’s leadership team, under President and Chief Executive Officer Rick E. Winningham, brings deep expertise in pharmaceutical R&D, regulatory affairs and commercial strategy aimed at delivering new therapeutic options to patients worldwide.View Theravance Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
